Stereotactic Radiosurgery for AMD: A Monte Carlo–Based Assessment of Patient-Specific Tissue Doses

Hanlon, J; Firpo, M; Chell, E; Moshfeghi, Darius M.; Bolch, Wesley E.

doi:10.1167/iovs.10-6421

Cited by 18 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale for such a RT approach is based on evidence that the rapidly proliferating neovascular endothelial cells that drive AMD development are relatively more radiosensitive than quiescent or less actively dividing cells [147,148]. The Oraya Therapy system can accurately deliver a radiation dose of up to 24 Gy to the radiosensitive choroidal neovasculature during a single treatment session, while maintaining dose limits to neighboring organs at risk [145,149]. A novel multimodality approach comprising Oraya Therapy of 16 or 24 Gy, and concomitant treatment with a VEGF inhibitor has also been developed [150] and implemented in clinical trials with no radiation-related adverse effects at 6 months [151–153].…”

Section: Emerging Gnrt Modalitiesmentioning

confidence: 99%

Targeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives

et al. 2014

View full text Add to dashboard Cite

Radiation therapy (RT) is the treatment of cancer and other diseases with ionizing radiation. The ultimate goal of RT is to destroy all the disease cells while sparing healthy tissue. Towards this goal, RT has advanced significantly over the past few decades in part due to new technologies including: multileaf collimator-assisted modulation of radiation beams, improved computer-assisted inverse treatment planning, image guidance, robotics with more precision, better motion management strategies, stereotactic treatments and hypofractionation. With recent advances in nanotechnology, targeted RT with gold nanoparticles (GNPs) is actively being investigated as a means to further increase the RT therapeutic ratio. In this review, we summarize the current status of research and development towards the use of GNPs to enhance RT. We highlight the promising emerging modalities for targeted RT with GNPs and the corresponding preclinical evidence supporting such promise towards potential clinical translation. Future prospects and perspectives are discussed.

show abstract

Section: Emerging Gnrt Modalitiesmentioning

confidence: 99%

Targeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives

et al. 2014

View full text Add to dashboard Cite

show abstract

“…They use random number generation and probability statistics to solve different physics- [91,92]. Although they are considered the most accurate and sensitive method for simulating radiation transport, the medical physics community recognizes the necessity to develop more sophisticated system [93].…”

Section: Stereotactic Radiosurgerymentioning

confidence: 99%

The role of simulation in neurosurgery

et al. 2015

View full text Add to dashboard Cite

Advances in imaging and computer technology have led to the development of different simulation models to complement traditional surgical training. Sophisticated virtual reality (VR) simulators with haptic feedback and impressive imaging technology have provided novel options for training in neurosurgery. Breakthrough training simulation using 3D printing technology holds promise for future simulation practice, proving high-fidelity patient-specific models to complement residency surgical learning.

show abstract

“…An active suction apparatus along with infrared markers tracks the eye in the X, Y, and Z planes or rotational angles. The device delivers the full dose to the plane of the macula (which is situated 150 mm from the robotically positioned and tracked X-ray tube aperture) within a 4-mm-diameter spot size [72][73][74][75]. Fig.…”

Section: Low-voltage Stereotactic Radiotherapy (Srt) In Amdmentioning

confidence: 99%

Brachytherapy in Neovascular AMD

Grewal

Vajzovic

2015

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Neovascular age-related macular degeneration (AMD) has a complex pathophysiology, and although anti-VEGF therapy has been one of the most significant and successful advances, it is not effective for all patients with neovascular AMD. The potential role of radiation in the management of neovascular AMD has been suggested for several years. While previous work focused on the role of radiation alone, recent trials have evaluated the role of ionizing radiation as a synergistic treatment with anti-VEGF drugs, with endpoints being to reduce choroidal neovascular lesions faster, preserve visual acuity, and extend the treatment interval between injections. We review the current evidence available for the safety and efficacy of radiation in conjunction with anti-VEGF treatment for neovascular AMD delivered using three approaches-epimacular brachytherapy involving a pars plana vitrectomy (Vidion Neovista, Inc., Newark, CA, USA), episcleral brachytherapy without a pars plana vitrectomy (Salutaris Medical Devices, Tucson, AZ), and low-voltage stereotactic radiotherapy (IRay,

show abstract

Stereotactic Radiosurgery for AMD: A Monte Carlo–Based Assessment of Patient-Specific Tissue Doses

Abstract: The computational assessment performed indicates that a previously established therapeutic dose can be delivered effectively to the macula with the scheme described so that the potential for complications to nontargeted radiosensitive tissues might be reduced.

Cited by 18 publications

References 38 publications

Targeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives

Targeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives

The role of simulation in neurosurgery

Brachytherapy in Neovascular AMD

Contact Info

Product

Resources

About